| Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Lunger John | Chief Patient Supply Officer | Jan 19 | Sale | 5.67 | 4,358 | 24,708 | 7,346 | Jan 19 09:01 PM | | Norry Elliot | Chief Medical Officer | Jan 19 | Sale | 5.67 | 2,111 | 11,968 | 3,539 | Jan 19 09:01 PM | | Rawcliffe Adrian | Chief Executive Officer | Jan 19 | Sale | 5.67 | 9,879 | 56,009 | 13,529 | Jan 19 09:00 PM | | Lunger John | Chief Patient Supply Officer | Jan 12 | Sale | 6.15 | 1,058 | 6,509 | 1,767 | Jan 12 09:01 PM | | Bertrand William C JR | Chief Operating Officer | Jan 12 | Sale | 6.15 | 2,234 | 13,744 | 3,768 | Jan 12 09:01 PM | | Rawcliffe Adrian | Chief Executive Officer | Jan 12 | Sale | 6.15 | 2,707 | 16,654 | 3,695 | Jan 12 09:00 PM | | Norry Elliot | Chief Medical Officer | Jan 12 | Sale | 6.15 | 841 | 5,174 | 1,396 | Jan 12 09:00 PM | | Bertrand William C JR | Chief Operating Officer | Jan 04 | Sale | 5.33 | 3,499 | 18,642 | 5,864 | Jan 05 09:01 PM | | Lunger John | Chief Patient Supply Officer | Jan 04 | Sale | 5.33 | 1,065 | 5,674 | 1,760 | Jan 05 09:02 PM | | Norry Elliot | Chief Medical Officer | Jan 04 | Sale | 5.33 | 845 | 4,502 | 1,392 | Jan 05 09:00 PM | | Rawcliffe Adrian | Chief Executive Officer | Jan 04 | Sale | 5.33 | 4,967 | 26,464 | 6,737 | Jan 05 09:00 PM | | Wood Gavin | Chief Financial Officer | Dec 14 | Buy | 0.69 | 24,000 | 16,550 | 57,000 | Dec 16 09:00 PM | | Bertrand William C JR | Chief Operating Officer | Dec 14 | Buy | 0.69 | 207,000 | 143,824 | 284,808 | Dec 15 09:00 PM | | Rawcliffe Adrian | Chief Executive Officer | Sep 01 | Sale | 8.51 | 2,776 | 23,637 | 3,076 | Sep 02 09:00 PM | | TAYTON-MARTIN HELEN KATRINA | Chief Business Officer | Aug 03 | Sale | 8.74 | 200,000 | 1,748,180 | 0 | Aug 04 09:02 PM | | Lunger John | Chief Patient Supply Officer | Aug 03 | Sale | 9.25 | 4,823 | 44,613 | 8,066 | Aug 04 09:02 PM | | Rawcliffe Adrian | Chief Executive Officer | Aug 03 | Sale | 9.25 | 2,788 | 25,789 | 3,064 | Aug 04 09:01 PM | | Wood Gavin | Chief Financial Officer | Jun 29 | Buy | 1.62 | 33,000 | 53,460 | 33,000 | Jun 30 09:01 PM | | Alleva Lawrence M | Director | Jun 09 | Buy | 1.89 | 12,900 | 24,381 | 12,900 | Jun 11 09:00 PM | | Noble James | Director | May 29 | Sale | 9.33 | 500,000 | 4,666,000 | 0 | Jun 02 09:30 PM | | Sonsini Peter W. | 10% Owner | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:55 PM | | SANDELL SCOTT D | 10% Owner | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:54 PM | | Florence Anthony A. Jr. | 10% Owner | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:52 PM | | MOTT DAVID M | Director | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:53 PM | | BASKETT FOREST | 10% Owner | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:51 PM | | Behbahani Ali | Director | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:52 PM |
|
